Cargando…
Niraparib in ovarian cancer: results to date and clinical potential
Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2, two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both sporadic and familiar. PARP is a family of enz...
Autores principales: | Caruso, Davide, Papa, Anselmo, Tomao, Silverio, Vici, Patrizia, Panici, Pierluigi Benedetti, Tomao, Federica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564880/ https://www.ncbi.nlm.nih.gov/pubmed/29081841 http://dx.doi.org/10.1177/1758834017718775 |
Ejemplares similares
-
Current status of bevacizumab in advanced ovarian cancer
por: Tomao, Federica, et al.
Publicado: (2013) -
Angiogenesis and antiangiogenic agents in cervical cancer
por: Tomao, Federica, et al.
Publicado: (2014) -
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
por: Papa, Anselmo, et al.
Publicado: (2016) -
Investigating Molecular Profiles of Ovarian Cancer: An Update on Cancer Stem Cells
por: Tomao, Federica, et al.
Publicado: (2014) -
Fertility drugs, reproductive strategies and ovarian cancer risk
por: Tomao, Federica, et al.
Publicado: (2014)